RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Rigel Pharmaceuticals - Stock

Rigel Pharmaceuticals Net Income 2024

Rigel Pharmaceuticals Net Income

-16.03 M USD

Ticker

RIGL

ISIN

US7665596034

WKN

766093

In 2024, Rigel Pharmaceuticals's profit amounted to -16.03 M USD, a -36.11% increase from the -25.09 M USD profit recorded in the previous year.

The Rigel Pharmaceuticals Net Income history

YEARNET INCOME (undefined USD)
2030e73.36
2029e80.51
2028e67.99
2027e59.04
2026e36.64
2025e10.91
2024e-16.03
2023-25.09
2022-58.6
2021-17.9
2020-29.7
2019-66.9
2018-70.5
2017-78
2016-69.2
2015-51.5
2014-90.9
2013-89
2012-98.8
2011-86
201037.9
2009-111.5
2008-132.3
2007-74.3
2006-37.6
2005-45.3
2004-56.3

Rigel Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Rigel Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Rigel Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Rigel Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Rigel Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Rigel Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Rigel Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Rigel Pharmaceuticals’s growth potential.

Rigel Pharmaceuticals Revenue, Profit, and EBIT History

DateRigel Pharmaceuticals RevenueRigel Pharmaceuticals EBITRigel Pharmaceuticals Net Income
2030e362.1 M undefined134.54 M undefined73.36 M undefined
2029e318.66 M undefined115.26 M undefined80.51 M undefined
2028e290.21 M undefined83.13 M undefined67.99 M undefined
2027e259.64 M undefined62.66 M undefined59.04 M undefined
2026e230.29 M undefined48.36 M undefined36.64 M undefined
2025e194.98 M undefined18.31 M undefined10.91 M undefined
2024e152.1 M undefined-8.92 M undefined-16.03 M undefined
2023116.88 M undefined-20.49 M undefined-25.09 M undefined
2022120.2 M undefined-54.3 M undefined-58.6 M undefined
2021149.2 M undefined-9 M undefined-17.9 M undefined
2020108.6 M undefined-29 M undefined-29.7 M undefined
201959.3 M undefined-69.1 M undefined-66.9 M undefined
201844.5 M undefined-72.7 M undefined-70.5 M undefined
20174.5 M undefined-79.6 M undefined-78 M undefined
201620.4 M undefined-64.4 M undefined-69.2 M undefined
201528.9 M undefined-51.7 M undefined-51.5 M undefined
20148.3 M undefined-81.9 M undefined-90.9 M undefined
20137.2 M undefined-87.8 M undefined-89 M undefined
20122.3 M undefined-99.4 M undefined-98.8 M undefined
20114.8 M undefined-86.4 M undefined-86 M undefined
2010125 M undefined35.3 M undefined37.9 M undefined
2009800,000 undefined-110.9 M undefined-111.5 M undefined
20080 undefined-136.7 M undefined-132.3 M undefined
200712.6 M undefined-79.5 M undefined-74.3 M undefined
200633.5 M undefined-43 M undefined-37.6 M undefined
200516.5 M undefined-47.9 M undefined-45.3 M undefined
20044.7 M undefined-56.9 M undefined-56.3 M undefined

Rigel Pharmaceuticals stock margins

The Rigel Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Rigel Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Rigel Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Rigel Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Rigel Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Rigel Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Rigel Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Rigel Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Rigel Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Rigel Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Rigel Pharmaceuticals Margin History

Rigel Pharmaceuticals Gross marginRigel Pharmaceuticals Profit marginRigel Pharmaceuticals EBIT marginRigel Pharmaceuticals Profit margin
2030e93.92 %37.16 %20.26 %
2029e93.92 %36.17 %25.27 %
2028e93.92 %28.64 %23.43 %
2027e93.92 %24.13 %22.74 %
2026e93.92 %21 %15.91 %
2025e93.92 %9.39 %5.6 %
2024e93.92 %-5.87 %-10.54 %
202393.92 %-17.53 %-21.47 %
202298.59 %-45.17 %-48.75 %
202199.33 %-6.03 %-12 %
202099.17 %-26.7 %-27.35 %
201998.48 %-116.53 %-112.82 %
201899.33 %-163.37 %-158.43 %
201793.92 %-1,768.89 %-1,733.33 %
201693.92 %-315.69 %-339.22 %
201593.92 %-178.89 %-178.2 %
201493.92 %-986.75 %-1,095.18 %
201393.92 %-1,219.44 %-1,236.11 %
201293.92 %-4,321.74 %-4,295.65 %
201193.92 %-1,800 %-1,791.67 %
201093.92 %28.24 %30.32 %
200993.92 %-13,862.5 %-13,937.5 %
200893.92 %0 %0 %
200793.92 %-630.95 %-589.68 %
200693.92 %-128.36 %-112.24 %
200593.92 %-290.3 %-274.55 %
200493.92 %-1,210.64 %-1,197.87 %

Rigel Pharmaceuticals Aktienanalyse

What does Rigel Pharmaceuticals do?

Rigel Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of drugs for the treatment of autoimmune diseases, inflammation, and cancer. It was founded in 1996 by Donald Payan. The company is headquartered in South San Francisco, California. Rigel Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Rigel Pharmaceuticals's Profit Margins

The profit margins of Rigel Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Rigel Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Rigel Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Rigel Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Rigel Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Rigel Pharmaceuticals Stock

How much profit has Rigel Pharmaceuticals made this year?

Rigel Pharmaceuticals has made -16.03 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -36.11% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Rigel Pharmaceuticals publish its earnings?

Rigel Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Rigel Pharmaceuticals?

The profits of Rigel Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Rigel Pharmaceuticals?

You can learn more about the earnings of Rigel Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Rigel Pharmaceuticals pay?

Over the past 12 months, Rigel Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Rigel Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Rigel Pharmaceuticals?

The current dividend yield of Rigel Pharmaceuticals is .

When does Rigel Pharmaceuticals pay dividends?

Rigel Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Rigel Pharmaceuticals?

Rigel Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Rigel Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Rigel Pharmaceuticals located?

Rigel Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Rigel Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Rigel Pharmaceuticals from 6/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/28/2024.

When did Rigel Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/28/2024.

What was the dividend of Rigel Pharmaceuticals in the year 2023?

In the year 2023, Rigel Pharmaceuticals distributed 0 USD as dividends.

In which currency does Rigel Pharmaceuticals pay out the dividend?

The dividends of Rigel Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Rigel Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Rigel Pharmaceuticals

Our stock analysis for Rigel Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Rigel Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.